Articles related to EMERGING THERAPIES

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

An early clinical experience report describes how one retina practice integrated photobiomodulation (PBM) for intermediate age-related macular degeneration, highlighting workflow considerations, patient selection challenges, reimbursement issues, and ongoing uncertainty regarding long-term benefit.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

A patient with advanced, treatment-resistant lung cancer experienced complete tumor disappearance after sodium selenite treatment and remained tumor-free for 10 years. The single case cannot establish efficacy, safety, or causality.

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.

A novel small molecule, CN045, promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis. The findings support an emerging strategy aimed at repairing damaged myelin, though clinical applicability remains unproven.